chevron_leftBack
As of 13 June 2026, Entrada Therapeutics, Inc. has a market cap of $457.92M USD, ranking #15744 globally and #2699 in the United States.
It ranks #1407 in the Healthcare sector, and #271 in the Biotechnology industry.
Key Stats
Market Cap
$457.92MUSD
Enterprise Value
$210.63MUSD
Revenue (TTM)
$25.42MUSD
EBITDA (TTM)
-$151.9MUSD
Net Income (TTM)
-$143.75MUSD
PS Ratio
17.9
PB Ratio
1.5
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Dipal Doshi
open_in_new
Employees
152
Founded
2016
IPO
29 Oct 2021
Website
entradatx.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -1.3% | -2.5% | 6.8% | 14% | 73% | 44% |
News
Loading...
TRDA Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
TRDA
Entrada Therapeutics Inc
ISIN: US29384C1080
Shares Out.:
Shares Outstanding:
38.821M1
Shares Float:
22.206M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
12.72 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Entrada Therapeutics, Inc.
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company’s Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Its preclinical product includes ENTR-601-44; ENTR-601-45; and VX-670. The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc., in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: AMGN
|
$182.42B
40K%
|
23.9
|
|
NASDAQ: GILD
|
$159.92B
35K%
|
19.0
|
|
NASDAQ: NTRA
|
$27.6B
6K%
|
-
|
|
NYSE: IQV
|
$26.3B
6K%
|
20.0
|
|
NASDAQ: UTHR
|
$25.03B
5K%
|
20.4
|
|
NASDAQ: MRNA
|
$18.13B
4K%
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
EBR: ARGX
|
$47.84B
10K%
41.39B EUR
|
39.9
|
|
KRX: 207940
|
$44.84B
10K%
68.19T KRW
|
35.5
|
|
ASX: CSL
|
$42.36B
9K%
60.27B AUD
|
29.3
|
|
SIX: LONN
|
$42.3B
9K%
33.71B CHF
|
37.2
|
|
KRX: 068270
|
$28.11B
6K%
42.76T KRW
|
43.8
|
|
NASDAQ: BNTX
|
$25.69B
6K%
|
-
|
chevron_leftBack